

## Data Sharing Statement

<b>Article Info</b>	<a href="http://dx.doi.org/10.21037/jtd-20-2855">http://dx.doi.org/10.21037/jtd-20-2855</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The survival data in particular will be shared。 Progression-free survival (PFS) of advanced NSCLC patients and Kaplan–Meier survival curves were applied to evaluate the short-term efficacy of anlotinib treatment in advanced NSCLC patients.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Three years within the publication date, since the technique or survival date may be updated over time.
7	To whom will you share the data?	Medical oncologists and researchers who are interested in studies the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: 372187133@qq.com

10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.
----	-------------------------	--